127 related articles for article (PubMed ID: 38482738)
1. Patterns of structural variants within TP53 introns and relocation of the TP53 promoter: a commentary
Beird HC; Lin D; Lazar AJ; Futreal PA
J Pathol; 2024 Jun; 263(2):131-134. PubMed ID: 38482738
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway.
Saba KH; Difilippo V; Kovac M; Cornmark L; Magnusson L; Nilsson J; van den Bos H; Spierings DC; Bidgoli M; Jonson T; Sumathi VP; Brosjö O; Staaf J; Foijer F; Styring E; Nathrath M; Baumhoer D; Nord KH
J Pathol; 2024 Feb; 262(2):147-160. PubMed ID: 38010733
[TBL] [Abstract][Full Text] [Related]
3. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
Alidousty C; Baar T; Martelotto LG; Heydt C; Wagener S; Fassunke J; Duerbaum N; Scheel AH; Frank S; Holz B; Binot E; Kron A; Merkelbach-Bruse S; Ihle MA; Wolf J; Buettner R; Schultheis AM
J Pathol; 2018 Sep; 246(1):67-76. PubMed ID: 29885057
[TBL] [Abstract][Full Text] [Related]
4. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
[TBL] [Abstract][Full Text] [Related]
5. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
6. Fluorescent In Situ Hybridization for TP53 in the Diagnosis of Pediatric Osteogenic Sarcoma.
Marrano P; Shago M; Somers GR; Thorner PS
Am J Surg Pathol; 2018 Jun; 42(6):744-749. PubMed ID: 29543677
[TBL] [Abstract][Full Text] [Related]
7. Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.
Lorenz S; Barøy T; Sun J; Nome T; Vodák D; Bryne JC; Håkelien AM; Fernandez-Cuesta L; Möhlendick B; Rieder H; Szuhai K; Zaikova O; Ahlquist TC; Thomassen GO; Skotheim RI; Lothe RA; Tarpey PS; Campbell P; Flanagan A; Myklebost O; Meza-Zepeda LA
Oncotarget; 2016 Feb; 7(5):5273-88. PubMed ID: 26672768
[TBL] [Abstract][Full Text] [Related]
8. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
[TBL] [Abstract][Full Text] [Related]
9. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
[TBL] [Abstract][Full Text] [Related]
10. Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA.
Niu G; Hellmuth I; Flisikowska T; Pausch H; Rieblinger B; Carrapeiro A; Schade B; Böhm B; Kappe E; Fischer K; Klinger B; Steiger K; Burgkart R; Bourdon JC; Saur D; Kind A; Schnieke A; Flisikowski K
Oncogene; 2021 Mar; 40(10):1896-1908. PubMed ID: 33603167
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era.
Soussi T; Leroy B; Taschner PE
Hum Mutat; 2014 Jun; 35(6):766-78. PubMed ID: 24729566
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants.
Pinto EM; Maxwell KN; Halalsheh H; Phillips A; Powers J; MacFarland S; Walsh MF; Breen K; Formiga MN; Kriwacki R; Nichols KE; Mostafavi R; Wang J; Clay MR; Rodriguez-Galindo C; Ribeiro RC; Zambetti GP
Mol Cancer Res; 2022 Feb; 20(2):207-216. PubMed ID: 34675114
[TBL] [Abstract][Full Text] [Related]
13. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma.
Shaul E; Roth M; Lo Y; Geller DS; Hoang B; Yang R; Malkin D; Gorlick R; Gill J
Cancer; 2018 Mar; 124(6):1242-1250. PubMed ID: 29313943
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
[TBL] [Abstract][Full Text] [Related]
16. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
17. Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma.
Negri GL; Grande BM; Delaidelli A; El-Naggar A; Cochrane D; Lau CC; Triche TJ; Moore RA; Jones SJ; Montpetit A; Marra MA; Malkin D; Morin RD; Sorensen PH
J Pathol; 2019 Nov; 249(3):319-331. PubMed ID: 31236944
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Maguire SL; Peck B; Wai PT; Campbell J; Barker H; Gulati A; Daley F; Vyse S; Huang P; Lord CJ; Farnie G; Brennan K; Natrajan R
J Pathol; 2016 Nov; 240(3):315-328. PubMed ID: 27512948
[TBL] [Abstract][Full Text] [Related]
19. Initial and crucial genetic events in intestinal-type gastric intramucosal neoplasia.
Rokutan H; Abe H; Nakamura H; Ushiku T; Arakawa E; Hosoda F; Yachida S; Tsuji Y; Fujishiro M; Koike K; Totoki Y; Fukayama M; Shibata T
J Pathol; 2019 Apr; 247(4):494-504. PubMed ID: 30474112
[TBL] [Abstract][Full Text] [Related]
20. TP53 intronic mutations in bovine enzootic hematuria-associated urinary bladder tumors.
Sasani F; Baghban F; Nikbakht Brujeni GH; Kazemi M
Vet Pathol; 2013 May; 50(3):543-7. PubMed ID: 23242803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
